discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Search
Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
Plasmid DNA Production | BioXcellence
Discover our range of plasmid DNA production solutions from research to GMP.
Social Support
People living with cancer share their perspectives on the importance of social support.
FuturePack
Boehringer Ingelheim has built a new special machine that enables efficient and sustainable packaging of small batches.
Our partners university of georgia
We're partnering with the University of Georgia to address unmet needs and find solutions to some of the biggest challenges in animal health.
About Us
About us
U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults
Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults
Building Successful Partnerships in Animal Health
Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.
New digital Tx collab with Click
New digital therapy collaboration with Click Tx
Poultry
Poultry
Newsbits
Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience.
Retinal Diseases
Retinal Diseases
Shared science for the best cat diabetes management
Diabetes mellitus is a common endocrine disease with increasing prevalence in dogs and cats. Learn how science's made management easier.
Company Culture
Company Culture
Joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
FOYA_Shanghai
Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
Embracing diversity in clinical trials
At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.
Living with pulmonary fibrosis and finding hope
From caregiver to co-founder of the European Pulmonary Fibrosis Federation, Liam Galvin shares about his experience, and the impact of ongoing research
Brazil boosts biosecurity in dairy farms
We partnered with Embrapa to help farmers and local authorities set best practices in biosecurity for dairy through a biosecurity certificate.
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
Outside the lab…inside the family
We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
AI&Data Science Fellowship Tuebingen
AI&Data Science Fellowship Tuebingen
Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.